Colombia’s regulated medical market entered a new phase in late 2025: the country formally recognized dried flower as a finished product for medical (and veterinary) use, enabling dispensing through licensed pharmacies and drugstores under a physician prescription. This is a meaningful expansion beyond extracts and oils—and it has immediate implications for cannabis compliance, pharmacy SOPs, quality systems, labeling, stability strategy, and export positioning.
This post breaks down what changed, what pharmacies and operators should start preparing now, and how the shift may reshape Colombia’s export mix—especially for EU‑GMP-aligned supply chains.
Focus keyword: Colombia pharmacies cannabis flower 2025 decree
What changed in 2025: flower becomes a regulated “finished product”
On October 27, 2025, Colombia issued Decree 1138 of 2025, modifying the medical framework housed within the health sector’s unified regulatory decree (Decreto 780 de 2016) as previously substituted by Decree 811 of 2021. The headline change: flower is explicitly recognized as a finished product for medical purposes, allowing it to be commercialized domestically through pharmacies/droguerías and certain veterinary establishments—subject to the applicable control and sanitary oversight.
Key official references:
This reform also resolves a long-standing inconsistency: Colombia had already opened pathways for export of dried flower under Decree 811 of 2021, but domestic commercialization of flower was constrained by regulatory ambiguity.
Implementation timelines: the “five‑month” rulemaking clock
Multiple public summaries of the decree point to a critical implementation detail: within five (5) months of the relevant article’s entry into force, the government is expected to issue supporting regulation and guidance—particularly for commercialization support and operationalization.
Industry and compliance teams should treat late 2025 through early/mid‑2026 as a build period for:
- Pharmacy SOPs and staff training
- Vendor qualification and inbound QA programs
- Packaging/label artwork updates
- Stability and shelf-life strategy for dried flower SKUs
- Track-and-trace / controlled-substance recordkeeping alignment
Who regulates what: the four‑agency compliance reality
Colombia’s medical framework is multi‑agency by design, and Decree 1138 reinforces that reality:
- MinSalud: health policy, technical regulations for access, and coordination for implementation.
- INVIMA: sanitary oversight for medicines/regulated products, certifications (e.g., GMP/BPM; pharmacy compounding certifications), inspections, and vigilance.
- FNE (Fondo Nacional de Estupefacientes): operational control and oversight for controlled substances, including registrations, quotas/cupos, and recordkeeping expectations.
- ICA: agricultural and phytosanitary control—especially important for export certification of plant-origin shipments.
Practical takeaway: even if your business “only” grows, manufactures, distributes, or dispenses, your compliance program must anticipate interoperability across these authorities.
Useful official starting points:
Pharmacy dispensing: SOPs to build now (storage, logs, verification)
Dispensing dried flower through pharmacies shifts the compliance center of gravity from “manufacturing only” to “retail healthcare operations under controlled-substance rules.” Pharmacies should prepare SOPs that combine:
- Pharmaceutical service standards (e.g., Colombia’s service framework in Decreto 2200 de 2005)
- Controlled-medicine controls (FNE/Fondo Rotatorio requirements and the broader controlled-substance rules)
- Product-specific quality and labeling controls appropriate for flower
Below are SOP elements that compliance teams should draft, validate, and train against.
Receiving & inbound quality verification
At receiving, pharmacies should confirm:
- Supplier authorization (appropriate license status and registration for controlled distribution)
- Batch identity (lot/batch number matching outer packaging)
- COA availability (certificate of analysis traceable to the same lot; ensure secure storage of COA files)
- Seal integrity (tamper evidence; evidence of opening or moisture compromise is a red flag)
- Storage conditions during transport where applicable (temperature/humidity excursions)
Storage & security controls
Dried flower introduces risks that are different from oils:
- Odor control and diversion risk
- Moisture sensitivity (mold risk if humidity rises)
- Light/heat sensitivity impacting potency/terpene profile
SOP essentials:
- Segregated controlled storage with restricted access
- Environmental monitoring appropriate for plant material (documented temperature and relative humidity targets)
- FEFO rotation (first‑expire, first‑out)
- Quarantine process for damaged packs, labeling defects, or COA mismatches
- Waste/destruction procedure aligned to controlled-substance handling
Dispensing workflow & patient verification
Because the model is prescription-driven, pharmacies should implement:
- Prescription validation checkpoints (prescriber identity, completeness, and validity)
- Patient identity verification prior to dispensing
- Quantity and refills controls (as applicable under controlled-substance rules and the prescription)
- Clinical counseling prompts (see “labeling & warnings” and “in-use stability” below)
Dispensing logs and inventory reconciliation
For controlled products, regulators typically expect auditable movement records. Pharmacies should implement:
- Per-lot perpetual inventory (receipts, dispensing, returns, waste)
- Daily/weekly reconciliation with defined tolerances and investigation triggers
- Exception reporting for shortages, damaged units, suspected diversion
- Document retention rules (align retention with applicable health and controlled-substance requirements)
Foundational pharmacy-service framework:
Labeling for dried flower: what “good” needs to look like
One of the biggest operational differences between flower and oils is the label. Oils often have standardized concentrations (e.g., mg/mL) and dosing devices. Flower introduces variability and requires tighter batch communication.
While your exact label content must follow what is approved/required for the product’s regulatory pathway, compliance teams should plan for labels that can support:
- patient safety
- pharmacy dispensing controls
- audit-ready traceability
Core label elements pharmacies and regulators will look for
At a minimum, expect to operationalize labels containing:
- Product identity (name; presentation as dried flower)
- Net content (weight)
- THC and CBD content expressed clearly (and ideally per gram and/or per unit weight)
- Batch/lot number
- Manufacturing/pack date and expiry date
- Storage conditions (temperature/humidity/light guidance)
- Warnings appropriate to a controlled, psychoactive medicine (e.g., impairment, driving, pregnancy, pediatric risk)
- Manufacturer/packager identification
- COA linkage (QR code or equivalent) tied to lot-specific results
INVIMA’s general position on registration/controls for regulated products underscores the need for proper sanitary authorization and compliant labeling through the relevant pathway:
Labeling design considerations unique to flower
Flower labels must handle additional realities:
- Batch-to-batch variability: even with strong cultivation control, flower lots can vary; labels should avoid implying a fixed dose without context.
- Moisture and microbial risk: storage warnings matter more; pack integrity must be emphasized.
- Multiple routes of administration: if inhalation is contemplated under medical supervision, warnings should be unambiguous.
Serialization & unit-level identification (export-forward planning)
Even if Colombia’s domestic rules do not require full pharmaceutical serialization for flower, companies targeting EU/UK channels should consider:
- unit-level unique identifiers
- scan-to-COA and scan-to-batch release records
- tamper evidence aligned with GMP expectations
This is less about marketing and more about defensible chain-of-custody in audits and import licensing reviews.
Stability & packaging strategy: flower is not oil
Dried flower behaves like a botanical drug substance/product with potency and quality attributes that can change with:
- oxygen exposure
- light
- temperature fluctuations
- humidity excursions
- repeated opening (“in-use” conditions)
Stability program takeaways for operators
For EU-facing quality expectations, stability strategies commonly align with ICH principles and herbal medicinal product guidance. A practical industry reference point highlights that stability programs for flower often include (at minimum):
- THC/CBD assay over time
- loss on drying (LOD) or moisture monitoring
- microbiological contamination testing
See: “Stability testing for medical Cannabis – What needs to be considered” (GMP Journal): https://www.gmp-journal.com/current-articles/details/stability-testing-for-medical-cannabis-what-needs-to-be-considered.html
Pack size decisions: compliance meets patient use
Pack-size choices affect both safety and quality:
- Smaller packs reduce in-use degradation and diversion exposure.
- Larger packs reduce per-unit packaging cost but increase repeated opening risk.
If multi-dose containers are used, companies should consider in-use stability justification and counseling language that reflects real-world handling.
Container/closure system matters more than most teams expect
For dried flower, packaging is part of the stability strategy:
- moisture barrier performance
- light protection
- headspace oxygen control
- tamper evidence
If you’re designing for export, you also need:
- GMP documentation for packaging components
- supplier qualification and change control
GMP and quality management: what changes when the end product is flower
Recognizing flower as a finished product pushes operators toward a more pharmaceutical posture:
- Defined specifications for identity, potency, microbiological quality, foreign matter, and contaminants
- Batch release discipline and deviation handling
- Change control for packaging, cultivation conditions, drying/curing parameters, and storage
EU‑GMP positioning
In the EU context, importers and regulators frequently expect EU‑GMP (or equivalent recognition) for the relevant manufacturing steps, along with a robust QMS and auditable batch documentation.
Colombian operators pursuing EU market share should ensure they can supply:
- GACP/GMP interface documentation (especially around drying/processing)
- validated cleaning and contamination control
- packaging line qualification
- stability data supporting shelf-life claims
For broader context on EU expectations around medicinal flower as a regulated product, see:
Historically, many exporters focused on oils/extracts because they are easier to standardize and dose. Domestic pharmacy dispensing of flower changes the commercial calculus.
1) New domestic demand can rebalance export inventory
As pharmacies begin dispensing flower under prescription, domestic demand may:
- absorb product previously destined for export
- require new cultivation/harvest planning around specific chemotypes
- increase the importance of consistent post-harvest SOPs (drying, trimming, packaging)
2) Documentation burden increases for flower exports
Exporting finished flower typically requires tighter alignment across:
- FNE controls (controlled-substance permissions)
- ICA phytosanitary certification for plant-origin goods
- VUCE workflows for export authorizations/“vistos buenos”
- quality documentation expected by destination country importers
Key export workflow references:
3) Chain-of-custody and GDP expectations become more visible
Even when not explicitly labeled as “GDP,” importers often expect distribution practices consistent with pharmaceutical norms:
- temperature/humidity controls during distribution
- secure transport
- documented handoffs
Domestic pharmacy distribution can help Colombia demonstrate maturity in regulated dispensary rollout—a narrative that matters for international buyers assessing reliability.
4) Competitive positioning in Europe and the UK
Europe remains a high‑value destination for medically regulated products, but it is document-heavy.
For UK market context on controlled drug licensing expectations:
For Germany, requirements can vary by interpretation across states and product classification, but the direction of travel remains quality- and permit-driven:
Compliance watchlist for late 2025: what to monitor
As Colombia operationalizes Decree 1138, compliance teams should actively monitor:
On vigilance: INVIMA has formal frameworks for adverse event reporting and pharmacovigilance obligations (not product-specific to flower, but relevant as patient access expands):
Practical takeaways for operators
For cultivators and manufacturers
- Treat dried flower as a finished medicinal product from a QMS perspective: specifications, batch release, stability, packaging qualification.
- Build export-ready documentation now: COA linkage, batch records, packaging component traceability.
- Prepare for domestic channel requirements that look increasingly like pharmaceutical distribution.
For pharmacies and dispensers
- Implement SOPs for receiving, secure storage, dispensing logs, and identity verification.
- Train staff on controlled-substance workflows and patient counseling for flower-specific risks.
- Use lot-level inventory systems that can stand up to audits.
For exporters and investors
- Expect a shift in Colombia’s form-factor strategy: flower can become a larger share of the regulated portfolio.
- EU/UK positioning depends on GMP discipline + documentation quality, not just cultivation cost advantages.
- Watch implementing regulations closely—timelines and technical requirements will determine how fast the dispensary rollout becomes real.
Not legal advice
This article is for informational purposes only and does not constitute legal advice. Regulations change, and implementation guidance may add or alter operational requirements.
Stay audit-ready with CannabisRegulations.ai
If your team is updating SOPs, labeling, stability plans, or export documentation in response to Colombia’s 2025 changes, use https://cannabisregulations.ai/ to track regulatory updates, build compliance checklists, and pressure-test your licensing and quality documentation before inspections or buyer audits.
